secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001680367-22-000031
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs Q3 net loss $24.6M; cash $185.1M; SL-172154 trial enrollment complete
--------------------------------------------------------------------------------

- Net loss of $24.6M ($0.58/share) vs $17.4M ($0.41/share) in Q3 2021, driven by higher R&D and G&A costs.
- Cash and investments $185.1M as of Sep 30, 2022, down from $268.8M at Dec 31, 2021; cash runway into H2 2024.
- Completed enrollment in Phase 1 monotherapy dose-escalation of SL-172154 in platinum-resistant ovarian cancer; final data expected midyear 2023.
- First patient dosed in Phase 1B combination trial of SL-172154 with liposomal doxorubicin in ovarian cancer; initial data expected midyear 2023.
- R&D expenses $18.9M (up 25% YoY); G&A $6.6M (up 53% YoY, including $1.4M litigation settlement).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036722000031/0001680367-22-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036722000031/sttk-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001680367-22-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer